Shots:
Oncolytics is expecting to receive the final PanCAN grant payment later this quarter following completion of certain activities in Cohort 5 of its P-I/II (GOBLET) study, alongside an update on the timing of clinical data release for pelareorep
The final Cohort 4 results are expected in Q4’26, which evaluates pelareorep with atezolizumab in 2L…
